|
|
Volumn 25, Issue 22, 2007, Pages 3382-3383
|
|
Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab [2]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
TRASTUZUMAB;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
COST BENEFIT ANALYSIS;
HEALTH ECONOMICS;
HUMAN;
LETTER;
MEDICAL LITERATURE;
PRIORITY JOURNAL;
QUALITY OF LIFE;
UNSPECIFIED SIDE EFFECT;
WOMEN'S HEALTH;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
COST OF ILLNESS;
COST-BENEFIT ANALYSIS;
FEMALE;
HUMANS;
ITALY;
MEDICAL ONCOLOGY;
PERIODICALS;
QUALITY-ADJUSTED LIFE YEARS;
UNITED STATES;
|
|
EID: 34548237742
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2007.12.3760 Document Type: Letter |
|
Times cited : (4)
|
|
References (8)
|
